Conventional cardiac risk factors associated with Trastuzumab induced cardio-toxicity in breast cancer: a meta-analysis

Abstract

Funding Acknowledgements: Type of funding sources: None. Background: Trastuzumab has had a major impact on the treatment of human epidermal growth factor receptor 2(HER-2) positive breast cancer patients. However, it is associated with cardiotoxicity, expressed as an asymptomatic decrease in LVEF and less often as clinical HF. Published studies have tried to identify risk factors predisposing to cardiotoxicity but the results are not uniform.